A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
Yanyan Hu,1 Sai-Hong Ignatius Ou2,3 1Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China; 2University of California Irvine School of Medicine, Orange, CA, 92868, USA; 3Chao Family Comprehensive Cancer Center, Orange, CA, 92868...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Dove Medical Press
2025-10-01
|
| Цуврал: | Lung Cancer: Targets and Therapy |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.dovepress.com/a-concise-review-of-the-approved-met-tkis-savolitinib-gumarontinib-veb-peer-reviewed-fulltext-article-LCTT |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|